Try Alerts Free   |   Login
Health Care › Surgical And Medical Instruments And Apparatus

ATEC Price Correlated With Financials For Alphatec Holdings

Free historical financial statements for Alphatec Holdings Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 40 quarters since 2012. Compare with ATEC stock chart to see long term trends.

ATEC Stock Compared to Quarterly

ATEC Income Statement

Revenue, Net:73962000
Revenue Per Share:0.7412
Cost of Goods & Services Sold:28737000
Gross Profit:45225000
Selling, General & Admin Expense:66692000
Research & Development Expense:8984000
Total Operating Expenses:83363000
Operating Income:-40186000
Income Taxes:1000
Net Income:-40187000
Earnings Per Share, Basic:-0.42
Shares Outstanding, Basic Avg:99786612

ATEC Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:8770000
Change in Accounts Receiveable:8724000
Net Cash from Operations:-14856000
Net Cash from Operations Per Share:-0.1489
Net Cash from Financing Activities:-487000
Property, Plant & Equipment Purchases:19598000
Net Cash from Investing Activities:-19997000
Net Change in Cash & Equivalents:-36620000

ATEC Balance Sheet

Cash and Cash Equivalents:187248000
Accounts Receivable, Net:41893000
Inventories:91703000
Total Current Assets:331157000
Property, Plant & Equipment, Net:87401000
Total Assets:572053000
Accounts Payable:25737000
Current Portion of Long-Term Debt:342000
Total Short-Term Liabilities:101095000
Long Term Debt, Non-Current Portion:326489000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Pritzker Jennifer N.   10% Owner
4,000 sh at $8
$31,840
Buy
Pritzker Jennifer N.   10% Owner
1,100 sh at $11
$11,704
Buy
Pritzker Jennifer N.   10% Owner
2,000 sh at $11
$22,840
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock Inc.
4,943,013 sh
34,257 sh
1%
$56,845
$738
Vanguard Group Inc
3,431,921 sh
77,959 sh
2%
$39,467
$1,132
First Light Asset Management, LLC
2,718,120 sh
392,635 sh
17%
$31,258
$4,678
Next Century Growth Investors LLC
2,127,475 sh
165,325 sh
8%
$24,465
$2,038
Cerity Partners LLC
1,585,008 sh
 
$18,228
Geode Capital Management, LLC
1,392,508 sh
108,148 sh
8%
$16,013
$1,333
Deutsche Bank Ag\
1,318,881 sh
207,464 sh
19%
$15,167
$2,463
King Luther Capital Management Corp
1,014,885 sh
313,073 sh
45%
$11,671
$3,649
New York State Common Retirement Fund
905,892 sh
-52,522 sh
-5%
$10,418
-$537
Morgan Stanley
797,081 sh
183,492 sh
30%
$9,166
$2,153
Principal Financial Group Inc
754,377 sh
173,103 sh
30%
$8,675
$2,031
Northern Trust Corp
694,583 sh
-39,421 sh
-5%
$7,988
-$401
Pier Capital, LLC
617,812 sh
219,157 sh
55%
$7,105
$2,548
Parkman Healthcare Partners LLC
451,794 sh
216,871 sh
92%
$5,196
$2,511
Rothschild & Co Asset Management Us Inc.
383,606 sh
-141,900 sh
-27%
$4,411
-$1,596
Envestnet Asset Management Inc
373,561 sh
-1,227 sh
0%
$4,296
$12
Mercer Global Advisors Inc /Adv
346,873 sh
 
$3,989
Pnc Financial Services Group, Inc.
316,628 sh
 
$3,641
Waypoint Capital Advisors, LLC
308,247 sh
308,247 sh
NEW
$3,739
$3,739
Royce & Associates Lp
254,000 sh
 
$2,921
COMPANY PROFILE
1. The Company and Basis of Presentation
The Company
Alphatec Holdings, Inc. (the “Company”), through its wholly owned subsidiaries, Alphatec Spine, Inc. (“Alphatec Spine”), SafeOp Surgical, Inc. (“SafeOp”), and EOS imaging S.A. (“EOS”), is a medical technology company that designs, develops, and markets technology for the treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The Company markets its products in the U.S. and internationally via a network of independent distributors and direct sales representatives.
Basis of Presentation
The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and include the accounts of the Company and its wholly owned subsidiaries. The Company translates the financial statements of its foreign subsidiaries using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. All intercompany balances and transactions have been eliminated in consolidation. The Company operates in one reportable business segment.
Reclassification
Certain amounts in the consolidated financial statements for the year ended December 31, 2020 have been reclassified to conform to the current year’s presentation. These reclassifications were immaterial and have no impact on previously reported results of operations or accumulated deficit.
Recent Developments
0.75% Senior Convertible Notes due 2026
In August 2021, the Company issued $316.3 million principal amount of unsecured senior convertible notes (the “2026 Notes”) with a stated interest rate of 0.75% and a maturity date of August 1, 2026. The net proceeds from the sale of the 2026 Notes were approximately $306.2 million after deducting the offering expenses. See Note 6 for additional information on the 2026 Notes.
Acquisition of EOS
On May 13, 2021, the Company acquired a controlling interest in EOS, pursuant to the Tender Offer Agreement (the “Tender Offer Agreement”) it entered into on December 16, 2020, and in June 2021 purchased the remaining issued and outstanding ordinary shares for a 100% interest in EOS. EOS, which now operates as a wholly owned subsidiary of the Company, is a global medical device company that designs, develops and markets innovative, low dose 2D/3D full body and weight-bearing imaging, rapid 3D modeling of EOS patient X-ray images, web-based patient-specific surgical planning, and integration of surgical plan into the operating room that collectively bridge the entire spectrum of care from imaging to post-operative assessment capabilities for orthopedic surgery. See Note 3 for additional information on the business combination.
COVID-19 Pandemic
In 2020, a novel strain of Coronavirus, which causes COVID-19, was identified and declared by the World Health Organization to be a pandemic. The virus causing COVID-19 has since rapidly spread across the globe to all countries, including to the United States. To slow the spread of COVID-19, governments have implemented measures, which include the mandatory closure of businesses, and restrictions on travel. In addition, many government agencies in conjunction with hospitals and healthcare systems have, to varying degrees, deferred or suspended elective surgical procedures. While certain spine surgeries are deemed essential and certain surgeries cannot be delayed, the Company has seen and may continue to see a reduction in procedural volumes as hospital systems and/or patients elect to defer spine surgery procedures and hospital systems experience staffing shortages.
The cumulative effect of these disruptions had an impact on the Company’s business during the years ended December 31, 2021 and 2020. The COVID-19 pandemic continues to evolve and its full impact on the Company’s business will depend on several factors that are uncertain and unpredictable, including, th

Data imported from Alphatec Holdings Inc. SEC filings. Check original filings before making any investment decision.